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1.1 Protocol Executive Summary 
1.1.1 Background 
The International Diabetes Federation (IDF) estimates that the number of adults with diabetes 
in Africa will escalate from 12.1 million to 23.9 million by the year 2030, a 98% increase1. 
Diabetic retinopathy (DR) has become a significant cause of blindness in developing countries 
because of longevity and decline in the other preventable causes of blindness2. DR diagnosed 
early, followed closely, and treated timeously with retinal laser therapy, prevents blinding 
proliferative retinopathy3. The effectiveness of this treatment suggests that there is the potential 
for a national screening programme to bring about a major reduction in blindness4 from DR in 
Botswana. 
1.1.2 Objectives 
This study of 223 participants will attempt to determine: 
1. The prevalence of DR among diabetics that present for screening.
2. The accessibility and acceptance of this screening programme.
3. Risk factors that are potential predictors of DR.
1.1.3 Methods 
A cross-sectional observational study design will be used with participant recruitment from 
diabetic patients attending the Gaborone Block 6 screening centre over a 5-week period. The 
participants will be interviewed using a questionnaire to determine; whether they have 
retinopathy, to collect baseline socio-demographic data as well as their access and acceptance 
of the screening service. Descriptive data will be reported for the predictor variables collected 
and a multivariate analysis will also be done to determine the risk factors associated with 
retinopathy.   
1.2 Introduction 
1.2.1 Diabetes mellitus- Significant public health problem 
The World Health Organisation (WHO) estimates that there are more than 170 million people 
with diabetes mellitus (DM) worldwide and this figure is expected to rise to 366 million in 
2030. The most rapid growth is expected in low and middle income countries amongst working 
age populations5. 
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The International Diabetes Federation (IDF) has estimated that the number of adults with DM 
in Africa will increase from 12.1 million to 23.9 million by the year 2030, a 98% increase. This 
is believed to be driven by the increase in urbanisation, sedentary lifestyles, obesity, population 
overgrowth and aging- as well as successes in combating communicable diseases in the region1. 
Sub-Saharan Africa, like the rest of the world, is experiencing an increasing prevalence of 
diabetes alongside other non-communicable diseases6. In addition, the region is still grappling 
with high rates of persistent communicable diseases such as HIV, TB and malaria7. DM must 
therefore compete for political attention and the limited financial resources. 
1.2.2 Diabetic retinopathy- A complication of Diabetes Mellitus 
Diabetes causes visual impairment through cataract and diabetic retinopathy (DR); a 
progressive disease of the retinal microvasculature. Retinopathy is thought to evolve through 
several stages, with background retinopathy progressing to maculopathy or proliferative 
retinopathy or a combination of the two8. Both maculopathy and proliferative retinopathy can 
independently lead to blindness. The challenge with DR is that it remains asymptomatic until 
it reaches advanced stages causing blindness in diabetic adults’ aged 20–74 years9. Without 
treatment, 50% of patients with retinopathy will become blind within 5 years10. The Diabcare 
Africa study carried out in 6 specialised diabetes centres found background retinopathy to be 
the leading eye complication [18%] followed by cataract [4%], amongst diabetic patients 
attending these centres11. 
1.2.2.1 Global estimates of diabetic retinopathy 
The importance of DR as a cause of blindness has increased because of the rise in DM 
prevalence, longevity and the decline in other preventable causes of blindness in developing 
countries2. DR is the fifth leading cause of blindness, globally affecting an estimated 1.8 billion 
people and is responsible for 4.8% of the blindness worldwide12. 
In recent years, due to better access to high quality cataract surgical services, DR is becoming 
a more significant cause of blindness11.  
1.2.2.2 African estimates of diabetic retinopathy 
In Africa, the prevalence of DR ranges from 17.9% in West African diabetic population13 to 
40.3% in rural regions of South Africa14.  
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The latter study found that the complication rate among rural South Africans was high and that 
more than 1 in 10 diabetics had severe retinopathy requiring laser. In 2012, a systematic review 
of the studies done in 21 African countries15 reported the prevalence of any retinopathy in 
patients with diabetes to be between 30.2-31.6%. The review also found proliferative DR to be 
0.9-1.3% and maculopathy 1.2-4.5%. 
1.2.3 Determinants and treatment of diabetic retinopathy 
The main risk factors for development of diabetic retinopathy are age, duration of diabetes and 
level of glycaemic control4. Photocoagulation is a very effective treatment in the prevention of 
blindness from sight threatening DR. Data from several randomised controlled trials (RCTs) 
performed in Europe and North America have shown that photocoagulation reduced the risk of 
blindness by up to 61% in the treated eye16. The effectiveness of this treatment suggests that 
there is the potential for a national screening programme to bring about a major reduction in 
blindness from retinopathy4. 
1.2.4 Situational analysis in Botswana 
Botswana, with a population is just over 2 million, has developed from one of the least 
developed countries at independence in 1966 to an upper-middle income country mainly due 
to its prudent use and management of mineral resources and a stable democratic government 
system17. Despite this, Botswana continues to face multiple challenges such as high HIV 
prevalence rates with an estimated sero-prevalence of 37% amongst adults; high mortality rates 
among both women and children; persistent poverty and high unemployment18.  
There has not been a study to determine the number of diabetics living in the country but using 
WHO global estimates for a middle income country, the prevalence is conservatively estimated 
to be 4% of the population,19 which translates to 80 000/2 000 000. Using prevalence of DR 
rate of 20% (8 000 per million population) and among these, it is estimated 5% will be blind 
(400 per million population).  
The only population based study to date, looking at visual impairment nationally found DR to 
be the second leading cause of blindness (20%) after cataract in adult’s aged 50 years and 
above20. Most of the prevalence data of DR from Botswana is limited to a few, mostly 
hospital/facility based studies. A survey in 2006 of diabetics attending a health facility in 
Botswana estimated the prevalence of retinopathy to be only 9.2% and was the third most 
common eye condition after refractive error and cataract21.   
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Another study completed in 2011, found the prevalence of DR to be 17.7% among the diabetics 
on the national screening register in Botswana22. 
1.2.4.1 Diabetic retinopathy screening service (DRSS) in Botswana 
Retinopathy diagnosed early, followed closely and treated timeously with retinal laser therapy 
prevents blinding proliferative retinopathy and most importantly blindness3. Therefore, both 
the IDF and WHO vision 2020 guidelines recommend early detection of DR by means of DR 
screening. The DRS Service in Botswana was developed by prevention of blindness program 
(PoB) in the ministry of health in October 2009 with the help of a UK based charity called 
Addenbrook’s Abroad23.  
The screening was first done at Princes Marina hospital, a Referral facility in Gaborone until 
end of 2011 when it moved to Block 6 clinic. The DRSS went national in 2012 and included 3 
additional screening sites, Donga Clinic in Francistown, Sekgoma Memorial Hospital in 
Serowe and Letsholathebe Hospital in Maun. Block 6 Clinic is still the designated “diabetic 
centre of excellence” and offers a comprehensive array of services for the overall management 
of diabetic patients. The DR screening is done by 2 trained ophthalmic nurses using a non-
mydriatic fundus camera. The nurses have also been trained to grade the pictures.  However, 
attendance has been consistently low at the clinic and the “did not attend” (DNA) rate is 
estimated to be around 30% .23 
1.3 Rationale 
Despite the low attendance rates for DR screening, the Botswana DRS programme has been 
expanded from one to four centres. This research therefore will provide useful information 
about the acceptability of this service to patients in Botswana. Additionally, the study may shed 
light into potential strategies to strengthen the programme. Data on DR from African settings 
is quite limited hence the results of this study will add to the available information on the 
disease in an African country. 
1.4 Study Objectives 
The primary objective of the study is to determine the prevalence of DR, its determinants and 
the accessibility of the screening services in a sample that is presumed to be representative of 
the diabetic community attending screening at Block 6 clinic.  
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The following objectives are outlined for the study: 
1. To determine the prevalence of any DR in the patients screened at the centre.
2. To determine the prevalence of referable DR amongst those that present to the screening
service.
3. To assess how well the patients presenting for screening manage their diabetes.
4. To determine the level of awareness of the availability of screening services.
5. To assess how acceptable the screening services are to the patients.
6. To explore the association between diabetic retinopathy on fundus camera findings and
other predictor variables.
1.5 Methodology 
1.5.1 Study design and setting 
The study is a cross-sectional study to be conducted at Gaborone Block 6 diabetic retinopathy 
screening clinic. The study will be for 5-weeks and will include every patient that arrives for 
DR screening services during that time and has consented to be included in the study. 
1.5.2 Population and recruitment 
The study population will be any diabetic above the age of 18years presenting to the eye clinic. 
Convenience sampling will be used where consecutive patients will be asked to participate in 
the study. Participation will be voluntary and no form of incentive will be provided for agreeing 
to enrol into the study. Eligible participants will be recruited from the clinic waiting area where 
explanation of the study and consent will be sought. The questionnaire will then be 
administered by the researcher(s) to each participant in one of the rooms available for use in 
the eye clinic. 
1.5.3 Inclusion Criteria 
Any patient arriving at block 6 clinic for screening for diabetic retinopathy with all the 
following can be enrolled into study: 
 Age of 18 years or older
 Physician diagnosed Type 1 or type 2 DM.
 Ability to give written informed consent for participation in the study.
 Referred to Block 6 from any another health facility, whether private or public.
 First time/repeat patients
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1.5.4 Exclusion Criteria 
 Pregnant females with gestational diabetes.
 Patients travelling alone who are unable to speak or with speaking difficulties that may
hinder understanding of the researcher.
1.5.5 Sample size 
The sample size is calculated using the expected prevalence of any retinopathy and 
maculopathy in the diabetic population to be 17.7%. This is based on a previous local study of 
the diabetics on the national screening database12. In addition to the expected proportion we 
will use a precision of 5% and a power of 80%. 
n= p (1-p) z2    = {0.177(1-0.177)1.962}/0.052 = 223 
          d2 
1.5.6 Data collection tools 
1.5.6.1 Questionnaire 
Since no existing validated tool exists that would meet all the study objectives, a questionnaire 
based on a review of the literature was developed. 
The questionnaire was developed in English but has also been translated into Setswana, which 
is the National language of Botswana. Most young people in Botswana can understand some 
form of English but since the majority of the study sample will be elderly, there is need for 
translating the data collecting tools to avert difficulty in communication. Once the information 
has been captured in Setswana services of a professional translator will be utilised to back 
translate to English so as to ensure accurate capturing of the information provided by the 
participants.   
The questionnaire contains 3 sections: 
a. Demographic data
b. Diabetic management information
c. Awareness and access to screening service
The designed questionnaire was piloted at the Block 6 diabetic centre of excellence clinic, with 
8 participants. These were diabetics attending the clinic for a variety of reasons, not necessarily 
for DR screening.  
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The purpose of the pilot was to determine whether the questions are understandable and 
interpreted as expected by participants. The tool was re-conceptualised following the pilot 
study to make sure that it captured what it was expected to.  
1.5.7 Reliability and Validity 
There is no validated questionnaire linked to our specific research question to ensure validity 
however, the tool has face and construct validity in that literature was reviewed to determine 
the variables affecting diabetics that choose to present at screening centres. Authors of similar 
studies were contacted and requests of the questionnaires they used were made to guide the 
development of our study questionnaire. 
Reliability was ascertained by piloting the survey to 8 patients attending the Diabetic centre of 
excellence in Gaborone. The questionnaire was translated into Setswana by the ophthalmic 
nurses who work at the clinic. This helped remove the communication barrier between 
interviewer and participant hence allowing for repeatability in responses. 
1.5.8 Potential study biases 
Study participants will be selected as they enter the clinic via convenience sampling hence 
possibly prone to selection bias. Therefore, those patients that already present to health 
facilities for treatment will be selected to enter study whilst others out in the community who 
do not routinely attend health facilities might be missed. There may be study relevant 
differences between patients who attend and those who don’t. Information bias can affect the 
study because the questionnaire is administered by the researcher, who is a doctor, and the 
participants might give responses that are socially acceptable rather than the truth. Especially 
in regards to their management of diabetes, patients may not be forthcoming if their 
management is not optimal. 
Associations between retinopathy and the predictor variables is prone to confounding because 
this is a prevalence study and causal relationships are a challenging to determine in such a study 
design.  
1.5.9 Measurement 
The main outcomes of interest are the number of diabetic participants with DR as a proportion 
of the study sample. We will analyse different predictor variables to determine their effect on 
the risk of DR in diabetic patients.  
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Table 1.1: The list and definition of variables that will be considered in the study. 
Name Scale Possible Values 
DEMOGRAPHICS 
Age Numerical - continuous ≥18 years 
Sex Categorical - binary male, female 
Fundus camera findings Categorical - nominal no retinopathy, any retinopathy, referable 
retinopathy 
Household occupants Numerical - continuous ≥1 
Marital status Categorical - nominal single, married, divorced, widowed 
Education level Categorical - nominal none, primary, secondary, tertiary 
Employment status Categorical - binary yes, no 
DM MANAGEMENT 
Duration of DM in years Numerical- continuous >0
On treatment/not on 
treatment 
Categorical - binary yes, no 
DM knowledge Categorical - ordinal poor, average, good 




Categorical - ordinal never, sometimes, most times, always 
DM alternative medicine Categorical - binary yes, no 
SCREENING SERVICE 
ACCESS 
Screening service access Categorical – nominal <30 minutes, 30-60 minutes, >60 minutes 
Screening history Categorical - binary yes, no 
Time of last screening Categorical - nominal first, 0-12 months, 12-24 months, >24 
months 
Reasons for delayed 
screening 
Categorical - nominal cost, distance, forgot, busy 
Appointment scheduled Categorical - binary <1 month, >1 month 
Understands screening 
reasons 
Categorical - binary yes, no 
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1.5.10 Potential benefits of study participation 
The benefits of participating in the study are that participant has an opportunity to speak about 
the non-clinical aspects of their condition and its management. Due to time and inadequate 
staffing constraints, it is not very often that patients are asked about their barriers to accessing 
quality health care. Study participants also inherently benefit from screening because a positive 
screening test would result in early management of the DR to avoid rapid progression to 
blindness.  
1.6 Data management plan and analysis 
Data will be collected by study personnel and recorded in participant questionnaires for entry 
into a Microsoft Excel database for storage. The data will be cleaned using pivot tables in excel 
and exported to STATA version 14.1 (Stata Corp. College Station Texas) for analysis. Raw 
data will be stored in a specified locked cupboard in Block 6 Clinic and only named study staff 
will have access to it. Each participant will be assigned a unique study number. The Microsoft 
Excel database will only use the study number and not the name of participant.  
The correlation between study number and respective name will be kept in the raw data format 
in a file that will be locked away at the study site. Confidentiality will be maintained at all 
times in the study and the name, address, telephone number, or any other direct personal 
identifiers will not identify the participant in the study records, except when required by law. 
The data collected remains the property of the ministry of health- Diabetic retinopathy 
screening programme.  
Basic descriptive statistics of the study sample will be reported i.e. age, sex, marital status, 
fundus camera findings, level of education and employment status. For each participant we will 
also report their overall DM management and their access to DR screening services. 
1.6.1 Objective 1 
We will report the prevalence of participants with any DR as a proportion of the study sample. 
1.6.2 Objective 2 
We will report the prevalence of participants with referable DR as a proportion of the study 
sample. 
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1.6.3 Objective 3 
We will report the number of participants in the different variables under the section of DM 
management (see Table 1.1) as a proportion of the study sample. 
1.6.4 Objective 4 
We will report the number of participants in the different variables under the section of 
screening services access (see Table 1.1) as a proportion of the study sample. 
1.6.5 Objective 5 
We will report the number of participants in the different variables under the section of 
screening services access (see Table 1.1) as a proportion of the study sample. 
1.6.6 Objective 6 
We will perform a multivariate analysis with DR as the outcome of interest on the various risk 
factors collected from the participants to determine their association with the DR outcome.  
1.7 Ethical considerations 
The primary ethical issues for the study are: 
1.7.1 Consent 
All participants above the age of 18 years will be required to give consent prior to entering the 
study. Consent will be taken in the participants’ language of choice and the consent forms will 
be available in English and Setswana. Consent will cover all aspects of the study, including 
data collection and reporting.  
The consenting process will consist of a detailed verbal description of the study as well as a 
written consent form and information sheet. Consent forms will be in triplicate, with one copy 
for the participant, one for the study personnel, and one for the study folder.  
1.7.2 Respect for persons 
Participation in the study is voluntary and participants may withdraw their participation from 
the study at any time. 
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1.7.3 Privacy 
The interviews will take place in a side room next to the eye clinic which has been kindly 
offered by the ophthalmic nurses for research purposes. In the room there will be a participant 
(with a family member if they request), 1 researcher who will administer the questionnaire and 
the translator if required.  
1.7.4 Confidentiality 
The questionnaire will have a name but only to triangulate the data with the retinal findings in 
the nurses log book, if need be. The health care worker who will assist with the translation into 
Setswana will also subscribe to the ethical conduct that governs their everyday practice at the 
clinic.  
The information gathered will only be seen by the study staff and nominated personnel 
involved with the analysis. When all the identifying data has been removed from the data, then 
the findings of the study may be shared with other stakeholders, if requested. 
1.7.5 Beneficence 
There is always the minimal risk of loss of confidentiality as with any study but no significant 
potential harm to the participants is foreseen in this study. As this is an observational study 
where participants will be asked about their knowledge of DR screening and diabetes care, 
participants may actually feel relieved that they have an opportunity to share their experience 
of their disease. After the questionnaire is administered, the participant may ask a few questions 
regarding the study, DRSS or DR. This allows for knowledge sharing with the participant as 
the researchers are well acquainted with the structure of the eye services in the public health 
sector. 
1.8 No fault insurance 
The participants in this study are covered by the no-fault insurance offered by the University 
of Cape Town. The participants’ parents or guardians will be informed of this during the 
consenting process and it is specified in writing on the information sheets. The University of 
Cape Town (UCT) undertakes that in the event of you suffering any significant deterioration 
in health or well-being, or from any unexpected sensitivity or toxicity, that is caused by your 
participation in the study, it will provide immediate medical care.  
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UCT has appropriate insurance cover to provide prompt payment of compensation for any trial-
related injury according to the guidelines outlined by the Association of the British 
Pharmaceutical Industry, ABPI 1991. Broadly-speaking, the ABPI guidelines recommend that 
the insured company (UCT), without legal commitment, should compensate you without you 
having to prove that UCT is at fault.  
An injury is considered trial-related if, and to the extent that, it is caused by study activities. 
You must notify the study doctor immediately of any side effects and/or injuries during the 
trial, whether they are research-related or other related complications. UCT reserves the right 
not to provide compensation if, and to the extent that, your injury came about because you 
chose not to follow the instructions that you were given while you were taking part in the study. 
Your right in law to claim compensation for injury where you prove negligence is not affected. 
However, it has to be noted that this study poses very little risk in terms of the health and well-
being of the participants since it is not an intervention trial. 
1.9 Funding 
The study does not have much expense hence the funding is will be covered by the Principal 
Investigator through her own expenses. 
1.10 Stakeholders and Dissemination strategy 
The University of Cape Town is the primary stakeholder as the research protocol has to 
successfully meet the ethical standards when dealing with human research. The school of 
public health and particularly the community eye health department will be very interested in 
the findings of this study as I am the first candidate to enrol into the Master of Public Health - 
Community Eye Health stream.  
The Botswana Ministry of Health (MOH) also requires the research protocol to be submitted 
to their ethics committee for approval. Seeing as the study will be based in one of the health 
facilities, the findings will be relevant to them and hence making them a significant 
stakeholder. Findings will be disseminated to the various stakeholders in the form of a 
preliminary report, and presentations at appropriate meetings and conferences if requested. An 
article will be submitted to a public health/eye health peer-reviewed journal. The abstract will 
also be submitted to the community eye health journal (CEH) read by ophthalmic health care 
workers in resource constrained regions of the world. 
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1.11 Logistics 
Provisional enquiries have indicated that there are on average 15-20 adults per day are screened 
at the Block 6 Clinic. We aim to recruit all patients that present for screening (averaging 90 
participants per week) and depending on the response rate (assumed to be >80%) the data 
collection for the study is likely to be completed within 1 month (November 2014-December 
2014). This time frame takes into consideration factors like slow recruitment rates amongst 
other challenges that could be encountered as the study progresses.  
 An outline of the proposed study time is given below: 
January 2015-February 2015 Data collection and Data capturing 
December 2015 Data cleaning and Baseline data exploration 
January 2016-March 2016 Final analysis, preparation of manuscript 
March 2017 Submission 
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1.13 Appendices 
1.13.1 Letter of Consent 
SCHOOL OF PUBLIC HEALTH AND FAMILY MEDICINE 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 
University of Cape Town 
Observatory 7925 
South Africa 
27 October 2014 
STUDY INFORMATION SHEET 
The prevalence and determinants of diabetic retinopathy in Botswana: findings from a 
screening programme. 
I am a graduate student enrolled with the University of Cape Town and am conducting a 
research study as part of the requirements of the Master’s degree in Public Health. 
 My study will be looking at Diabetic Retinopathy (DR) which is a disease that may cause visual 
impairment or even blindness in Diabetics. In DR, the high levels of sugar in the blood can 
cause damage to the blood vessels in the back of the eye (retina) which then affects the vision. 
The risks for developing DR are increased number of years lived with the disease as well as 
poor control of blood sugar.  
DR is a painless disease and most times people are not aware that there is any damage until 
their vision begins to deteriorate. Therefore, all diabetics are encouraged to attend for annual 
screening for DR which involves checking the vessels of the retina for early changes with a 
camera.  
If no changes are seen, you will be asked to continue attending for annual DR screening and 
continue to take good control of your blood sugar. If any changes are seen, you will be sent to 
a specialist eye doctor who may perform laser treatment to the back of the eye. 
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Purpose of the study 
 To determine the prevalence of Diabetic retinopathy amongst those attending for
screening at block 6 Clinic.
 How well do those that present for screening manage their Diabetes
 Lastly, the acceptance as well as the access of the screening programme by
patients/diabetics in Botswana will also be assessed.
You are invited to take part in our study as we believe that your input would be valuable for 
our study and improve our knowledge and understanding about the issues affecting Diabetics 
with regards to screening their eyes for Diabetic retinopathy. This information can be used to 
improve the programme and hopefully contribute towards reducing blindness from Diabetic 
Retinopathy in Botswana. 
Procedures 
If you volunteer to participate in this study, we would ask you to be available for a brief (10 
minute) interview with the researcher(s) at Block 6 Clinic. 
In order for the retina to be seen clearly, some eye drops will be instilled into your eye before 
the eye examination. These drops will help dilate the pupil of your eye, which is the black hole 
in the front of the eye.  
Potential risks and discomforts 
The eye drops used for dilating the eye may cause sensitivity of light to the eye. This is 
temporary and the effects should ware off after an hour or two. You may wear sunglasses if 
you still feel some sensitivity to the light. If you continue to experience the sensitivity please 
inform one of the eye nurses who will assist you accordingly. 
Potential benefits to subject 
There are no direct benefits to you, financial or otherwise, for participating in this study. 
Confidentiality/Privacy 
Your involvement in this study is for research purposes only. All the data collected in this study 
will be treated as strictly confidential. No names will be used in the publications 
Confidentiality will be ensured by making the collected data available only to the main 
researchers, research assistants and participants themselves. 
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Rights of study participant 
Your participation is entirely voluntary (of your own choice) and refusal to participate will not 
be held against you. There will be no penalty in the event that you decide to withdraw from the 
study or refuse to answer any question that you feel uncomfortable answering. 
You are not waiving any legal claims or rights because of your participation in this research 
study. Please feel free to ask any questions regarding your rights as a research participant and 
any concerns you may have. If you understand and are satisfied with the information above, 
and wish to take part in the study, please fill in your name and signature and return the Consent 
Form below. 
If you have any further inquiries regarding the study please feel free to contact any of the 
researchers listed below. 
Dr Nuru Omari – nuru.hussein@gmail.com or mobile number (+267) 73792033 
Prof Cook - colin.cook@uct.ac.za 
Dr Nkomazana- nkomazanao@mopipi.ub.bw 
You may also contact the University of Cape-Town (UCT) Human Research Ethics Committee 
(HREC) on 021 406 6338 in case participants have any questions regarding their rights and 
welfare as research subjects on the study.  
CONSENT FORM FOR PARTICIPATION IN THE STUDY 
 The information above was described to me by __________________________ in 
__________________________ and I am fluent in this language. 
I hereby voluntarily agree to participate in the research study. The purpose and procedures of 
the study have been explained to me. I understand that my participation is voluntary and that I 
may refuse to answer any particular items or withdraw from the study at any time without any 
negative consequences. I also understand that my responses will be kept confidential.  
Name of participant: ______________________Date: __________________________ 
Signature: __________________________ 
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1.13.2 Participant questionnaire 
PARTICIPANT QUESTIONNAIRE 
PARTICIPANT DETAILS 
Q1 Name of participant 
Q2 Participant ID 0000/XX 
Q3 Enrolment date DD/MM/YYYY 
Q4 Home (Living) Address _______________________________ 
_______________________________ 
Q5 Contact Number 
Q6 Age at enrolment  00        years 





1 = no 
retinopathy 
2 = any 
retinopathy 





How many people 
live with you at 
home? 
1 = 1-5 people 2 = 6-10 people 3 = >10
people 
MARITAL STATUS   
Q10 What is your 
current marital 
status? 
1 = single, never 
married 
2 = married/ domestic 
partnership 






1 = never 
attended school 
2 = completed 
primary school 
3 = completed 
secondary school 




Q12.1 Are you 
currently 
employed? 
0 = no 1 = yes 
Q12.2 
If Yes, what is 
your occupation? 
DIABETES MELLITUS MANAGEMENT 
DM HISTORY 
Q13 
How many years have you been 
living with DM? 
DM MANAGEMENT 
Q14 Do you regularly get followed up by 
your doctor for DM management? 
0 = no 
1 = yes 
CARETAKER 
Q15 
Who helps you take 
care of your health? 
1 = I take 
care of 
myself 




How do you rate your 
understanding of 
Diabetes? 
1 = poor 2 = average 3 = good 
DM MEDICATION 
Q17.1 
What DM treatment 
are you currently 
taking? 
1 = diet & 
exercise 
control 
2 = oral 
medication 
only 
3 = insulin 
only 
4 = oral & 
injectable 
Q17.2 
If none of the above, 




Do you regularly use 
your treatment as 
directed by your health 
care provider? 
1 = never 2 = sometimes 3 = most times 4 = always 
ALTERNATIVE MEDICINE 
Q19.1 Are you taking any traditional 
medicine for your DM? 
0 = no 
1 = yes 
Q19.2 If so, what are you taking? 
ACCESSIBILITY OF SCREENING SERVICES 
ACCESS 
Q20 How far did you have to travel 
to come here today? 
1 = <30 
minutes 
2 = 30-60 minutes 3 = >60 minutes 
SCREENING HISTORY 
Q21 Is this the first time having a picture 
taken of the back of your eyes? 
0 = no 
1 = yes 
Q22 When was the last time you had a 
picture of the back of your eyes taken? 
1 = 1st 
time 
2 = 0-12 
months ago 
3 = 13-24 
months ago 
4 = >24 
months ago 
Q23 If >12 months ago, what was 
the reason for the delay? 
1 = cost 
2 = distance 3 = forgot 
appointment 
4 = busy at 
the time 
5= Other 
Q24 This time, how long ago were 
you told to come here?  
1 = <1 month ago 
2 = > 1 month ago 
Q25 If >1 month ago what was 
the reason for this delay? 
1 = 
cost 
2 = distance 3 = forgot 
appointment 
4 = busy at 
the time 
5 = Other 
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Q26 Do you feel you understand the 
importance of this service to 
diabetics? 
0 = no 
1 = yes 
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1.13.3 Ethics approval letter 
1.13.4   MEAJO Journal Submission Guidelines 
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ABBREVIATIONS 
DM Diabetes mellitus 
IDDM Insulin dependent diabetes mellitus 
NIDDM Non-insulin dependent diabetes mellitus 
DR Diabetic retinopathy 
DME Diabetic macular Oedema 
STDR Sight threatening Diabetic Retinopathy 
DRS Diabetic retinopathy screening/ Diabetic retinopathy study 
ETDRS Early treatment diabetic retinopathy study 
DRSS Diabetic retinopathy screening service 
NCD Non communicable diseases 
PI Protease inhibitor 




2.1.1 Definition and classification of Diabetes 
The term diabetes mellitus describes “a metabolic disorder of multiple aetiology characterized 
by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both”1. The long term exposure to 
hyperglycemia is associated with damage, dysfunction, and failure of various end organs, 
particularly the eyes, kidneys, nerves, heart, and blood vessels2. 
Classification of Diabetes Mellitus (DM) is more accurate if based on clinical progression and 
aetiology hence previously used terms such as insulin dependent diabetes mellitus (IDDM) and 
non-insulin dependent diabetes mellitus (NIDDM) have been eliminated from the current 
terminology3. These terms were a cause of confusion and frequently resulted in patients being 
classified based on treatment rather than pathogenesis. Following the expert committee 
meeting on the diagnosis and classification of DM, the terms type 1 and type 2 diabetes mellitus 
replaced IDDM and NIDDM, respectively4. 
2.1.2 DM- Significant public health problem 
The World Health Organisation (WHO) estimates that there are more than 170 million people 
with diabetes mellitus (DM) worldwide and this figure is expected to rise to 366 million by the 
year 2030. The most rapid growth is expected in low and middle income countries amongst 
working age populations5. Currently, more than two thirds of people with diabetes live in low 
and middle income countries6. 
The International Diabetes Federation (IDF) has estimated that the number of adults with DM 
in Africa will increase from 12.1 million to 23.9 million by the year 2030, a 98% increase. This 
is believed to be driven by increasing urbanisation, sedentary lifestyles, obesity, population 
overgrowth and aging- as well as successes in combating communicable diseases in the region7.  
Therefore, it is not surprising that there is a variation in prevalence frequently observed 
between rural and urban populations 8;9 with the latter showing higher prevalence of diabetes 
mellitus. A survey in Kenya recorded DM prevalence rates of 2% in rural regions compared to 
12% in urban regions10. Sub-Saharan Africa (SSA), like the rest of the world, is experiencing 
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an increasing prevalence of diabetes alongside other non-communicable diseases, a so called 
“double burden” of disease11.  
The region is still grappling with high rates of persistent communicable diseases such as HIV, 
TB and malaria12, DM must therefore compete for political attention and the limited financial 
resources. Type 2 diabetes is the predominant form of diabetes in SSA and accounts for more 
than 90% of the cases, whilst type 1 diabetes mellitus, gestational diabetes and other specific 
types constitute less than 10%13. Risk factors for the development of T2DM include obesity, 
ageing, and physical inactivity, often arising as a result of socioeconomic dynamics14.  Recent 
evidence suggests that antiretroviral treatment is associated with an increase in obesity and 
insulin resistance12, showing that communicable and non-communicable diseases are not 
separate entities as once considered. Conversely, the risk for infections such as pneumonia, TB 
and sepsis are also likely to increase in the Diabetic population15. 
2.1.3 TB and HIV infections associated with Diabetes Mellitus 
HIV infected persons are at increased risk of developing type 2 DM because of viral coinfection 
and adverse effects of treatment16. Protease inhibitor (PI) therapy for HIV-1 infection is in 
some cases associated with lipodystrophy syndrome in which type 2 DM and hyperglycaemia 
is a feature17. A prevalence of lipodystrophy of upto 83% in one study after only 21 months 
was concerning since ARV treatment is intended to be lifelong17. The same study found 
Diabetes mellitus was diagnosed in 7% of protease inhibitor recipients and impaired glucose 
tolerance in a further 16%. Recent data shows that another class of ARVs, the nucleoside 
analogue reverse transcriptase inhibitors (NRTI), also contribute to increased insulin 
resistance18.  
In recent decades, tuberculosis has increasingly become a problem in low-income countries, 
particularly those with HIV epidemics19. Despite the availability of effective therapy, 
tuberculosis (TB) continues to infect an estimated one-third of the world’s population, causing 
disease in 8.8 million people per year, and 1.6 million of those afflicted end in fatality20. A 
number of large studies involving thousands of participants provide convincing data that 
diabetes mellitus is a moderate-to-strong risk factor for the development of active tuberculosis 
21;22;23. 
6 
A WHO review done in 2008 found that diabetics compared to non-diabetics had a 3-fold risk 
of developing active TB24. In the setting of the increasing populations at risk of both diseases, 
the combination of TB and DM represents a worldwide health threat but particularly in 
developing nation where health systems struggle to meet the health challenges25.  
2.1.4 Diabetes and Obesity 
WHO estimates that globally there are more than 1 billion overweight adults and at least a third 
of them are obese26. Until recently, it has been perceived that obesity is a problem faced by 
developed countries, however, the complications of over-nutrition are increasing even in 
countries where hunger is endemic27. In developing countries undergoing health or 
epidemiological transition, a malnutrition pattern is predominantly emerging that is 
characterized by under-nutrition in children and ever-increasing obesity in adults28;29, 
particularly adult females30. 
In Africa, being overweight and obese have traditional and cultural undertones31. In South 
Africa for instance, being obese is seen to reflect affluence and happiness in many regions of 
the population32. It was observed in the study that overweight or obesity in women reflected 
on a husband’s ability to care for his wife and family. Overweight and obesity are also thought 
to reflect persons who are healthy and without HIV/AIDS33. It is clear that these beliefs present 
complexities in the prevention and management of obesity in the African context. 
2.1.5 Outcomes of diabetes mellitus 
Nearly 50% of all people with Diabetes are unaware that they have the condition34, meaning 
damage may have already occurred even at diagnosis. The risk of developing vascular 
complications of diabetes increases with increasing concentrations of hyperglycaemia35. There 
is strong evidence from cohort studies of diabetic populations that in addition to duration of 
diabetes and metabolic control, blood pressure, cholesterol and ethnic/genetic factors are the 
main known determinants of vascular complications36.  
Microvascular complications which include retinopathy, nephropathy and neuropathy are more 
common and occur earlier in the course of the disease37. Patients of African origin are thought 
to be at greater risk of developing these complications compared to Caucasians38.  
7 
Macrovascular complications of diabetes such as cardiovascular disease are considered 
relatively less common in Africa despite a high prevalence of hypertension39, although there 
is recent evidence to suggest increasing burden of cardiovascular disease on the continent40. 
IDF estimates that, in 2015, five million people died from causes associated with diabetes, that 
is more than all the deaths from malaria, tuberculosis and HIV combined41.  
Mortality associated with diabetes is significant in SSA, a systematic review found the 5-year 
mortality ranged from 4-57% in the region12. This figure may have underestimated or 
overestimated the true value due to the bias of sampling only selected diagnosed diabetic 
patients accessing healthcare. It is not surprising that the complications of diabetes also account 
for the staggering cost of treating diabetes, estimated at over US $670 billion dollars a year42. 
2.2 Diabetic retinopathy 
2.2.1 Diabetic retinopathy - A complication of Diabetes Mellitus 
Diabetic eye disease comprises a group of eye conditions that affect people with diabetes, 
namely, diabetic retinopathy, diabetic macular edema (DME), cataract, and glaucoma43.
Retinopathy is the most common cause of vision loss among diabetics and is thought to evolve 
through several stages. Background retinopathy progresses to either DME or proliferative 
retinopathy (PDR) or a combination of the two44. Both DME and PDR can independently lead 
to blindness hence they are sometimes collectively referred to as “sight threatening DR 
(STDR)”. Without treatment, 50% of patients with proliferative diabetic retinopathy (with 
retinal neovascularisation) will become blind within 5 years45.  
The challenge with DR is that it remains asymptomatic until it reaches advanced stages causing 
blindness in diabetic adults’ aged 20–74 years46, making it the leading cause of blindness 
amongst working age adults. At diagnosis, 21–25% of type 2 patients and 9.5% of type 1 
patients have some form of retinopathy47. Recently, the DR barometer report found that 1 in 3 
people with diabetes has diabetic retinopathy and 1 in 10 have STDR48. Retinopathy is so 
characteristic of diabetes that its presence had previously been incorporated into the definition 
of NIDDM; ‘only hyperglycaemia of sufficient magnitude to be associated with retinopathy is 
classified as NIDDM whilst lower levels that are not associated with retinopathy are classified 
as impaired glucose tolerance49. 
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The main risk factors for development of diabetic retinopathy are age, duration of diabetes and 
level of glycaemic control50. The UK prospective diabetes study, a landmark study in our 
current understanding of the prevention and treatment of DR, showed that lack of control of 
hypertension and elevated cholesterol worsened the progression of DR36. 
2.2.2 Prevalence estimates of diabetic retinopathy 
The importance of DR as a cause of blindness has increased due to the rise in DM prevalence, 
longevity and the decline in other preventable causes of blindness in developing countries51. 
DR is the fifth leading cause of blindness, globally affecting an estimated 1.8 billion people 
and is responsible for 4.8% of the blindness worldwide52. In recent years, due to better access 
to high quality cataract surgical services, DR is becoming a more significant cause of 
blindness53.   
The Diabcare Africa study carried out in 6 specialised diabetes centres found background 
retinopathy to be the leading eye complication [18%] followed by cataract [4%], amongst 
diabetic patients attending these centres53. The prevalence of diabetic retinopathy varies from 
16 to 77% depending on the duration of diabetes and glycaemic control54. In west Africa for 
instance, the prevalence of DR was estimated to be 17.9% amongst diabetic population55 whilst 
in South Africa 40.3% in rural regions was the prevalence56. The latter study found that the 
complication rate among rural South Africans was high and that more than 1 in 10 diabetics 
had severe retinopathy requiring laser treatment. In 2012, a systematic review of the studies 
done in 21 African countries57 reported the prevalence of any retinopathy in patients with 
diabetes to be between 30.2-31.6%. The review also found proliferative DR to be 0.9 - 1.3% 
and maculopathy 1.2-4.5%. 
2.2.3 Prevention and treatment of DR- Results from landmark trials 
The diabetes control and complications (DCCT) trial conclusively demonstrated the role of 
intensive glycaemic control in the prevention and progression of DR in diabetics. Study 
participants who kept their blood glucose level as close to normal were significantly less likely 
than those without optimal glucose control to develop diabetic retinopathy, as well as kidney 
and nerve diseases58. Treatment for diabetic retinopathy is often delayed until it starts to 
progress to sight threatening DR59. Treatment methods include photocoagulation, anti-
VEGF/steroid injections, vitrectomy surgery or a combination of them. Laser photocoagulation 
has been shown to be a very effective treatment in the prevention of blindness from sight 
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threatening DR60. The Diabetic retinopathy study61 (DRS) of 1976 found pan-retinal laser
photocoagulation had reduced the 2-year risk of blindness by about 60%. Another trial 
followed, the ETDRS study which had over 3700 participants, demonstrated that effective 
treatment for diabetic retinopathy could reduce severe vision loss by 90%.  
Focal laser therapy showed a 50% reduction in visual loss in those with DME62. Something of 
significance noted in that trial was that adverse effects of scatter photocoagulation on visual 
acuity and visual field were also observed. That proved the need for the inclusion of non-laser 
therapy in the overall management of DR.    
2.2.4 Grading of Diabetic Retinopathy 
Most classification systems for DR are based on landmark studies that tracked the appearance 
and progression of the disease62. 
Table 1. Diabetic retinopathy disease severity scale based on the ETDRS classification system 
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2.3 Screening Programme for Diabetic Retinopathy 
The effectiveness of treatment suggests that there is potential for a national screening 
programme to bring about a major reduction in blindness from retinopathy63. Efficient 
identification of diabetic retinopathy is also cost-effective as numerous modelling studies 
demonstrate potential savings of hundreds of millions of dollars if an evaluation results in 
appropriate photocoagulation64. 
The gold standard for the detection and classification of diabetic retinopathy is stereoscopic 
color fundus photographs in 7 standard fields, as defined by the Early Treatment Diabetic 
Retinopathy Study (ETDRS) group62. Although this technique is accurate and reproducible, it 
is labour intensive and requires skilled photographers; skilled photograph readers; and 
sophisticated photography equipment, film processing, and archiving65. The turnaround time 
from acquisition of the data to interpretation can take weeks in clinical trials and therefore may 
not be appropriate in a busy screening clinic. In short, 7-field stereoscopic fundus photography 
technique serves well as the standard with which to compare other screening technologies. 
Single-field fundus photography interpreted by trained readers is used to detect retinopathy that 
requires referral to an ophthalmologist; it is not used to comprehensively grade the level of 
retinopathy in the eye66. It requires less time and less light (only one flash is required), and 
unlike photography of multiple fields, it may not require mydriasis in the majority of patients67. 
One advantage of single-field fundus photography is the convenience to patients who do not 
have vision-threatening retinopathy. Therefore, the use of single-field photography may be a 
cost-effective way to use ophthalmic services because only patients with vision-threatening 
retinopathy are referred to an ophthalmologist. 
2.4 Patient self-management of Diabetes Mellitus 
Our health care system is designed to deliver acute, symptom driven care and therefore it is not 
surprising that physicians struggle to give the recommended level of DM care, especially in a 
busy office setting. Patients with chronic conditions such as diabetes self-manage their illness 
and are ultimately in control of their illness68. 
Regardless of what we as health professionals do or say, they control important self-
management decisions such as what to eat, to exercise or not or even whether to be compliant 
with prescribed medication69. This knowledge has led to the development of a new paradigm 
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of thinking, a so called “partnership” between patient and physician as opposed to traditional 
thinking where the doctor is regarded as the “expert”. Health systems in developed nations 
have started to adopt the view that chronic disease sufferers are their own principal caregivers 
and the health care worker is merely a consultant to support them in this role70. Diabetes 
education has been considered an important part of clinical management for many decades and 
Interventions that involve patient collaboration are now found to be more effective than 
didactic interventions in improving glycemic control, weight, and lipid profiles68.  
Improved patient attitudes towards their disease and appreciation of the need for psychosocial 
wellness of the patient are needed in order to ensure better health outcomes for diabetics71. We 
have come a long way from the times when it was believed that just the acquisition of diabetes 
knowledge alone, was sufficient to ensure patient compliance, it has proven to be much more 
complicated than that. 
2.5 Situational analysis in Botswana 
Botswana, with a population of just over 2 million, has developed from one of the least 
developed countries at independence in 1966 to an upper-middle income country mainly due 
to its prudent use and management of mineral resources and a stable democratic government 
system72. Despite this, Botswana continues to face multiple challenges such as high HIV 
prevalence rates with an estimated sero-prevalence of 37% amongst adults; high mortality rates 
among both women and children; persistent poverty and high unemployment73.  
Overall urbanization in Botswana has increased from 54 percent in 2001 to 64 percent in 2011. 
The major driver of urbanization in Botswana is the reclassification of its villages to an urban 
status, about 64 percent of the urban population resides in urban villages74. This was a positive 
development for the nation because the new urban villages were then entitled to the allocation 
of better infrastructure and social services. 
Figure 1. The national urban-rural tipping point between 1999 and 2000, when over half of the 
national population became classified as urban74.  
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There has not been a study to determine the number of diabetics living in the country but using 
WHO global estimates for a middle income country, the prevalence is conservatively estimated 
to be 4% of the population75, which translates to 80 000/2 000 000. Using prevalence of DR 
rate of 20% (8 000 per million population) and among these, it is estimated 5% will be blind 
(400 per million population). The only population based study to date, looking at visual 
impairment nationally found DR to be the second leading cause of blindness (20%) after 
cataract in adult’s aged 50 years and above76. 
Most of the prevalence data of DR from Botswana is limited to a few, mostly hospital/facility 
based studies. A survey in 2006 of diabetics attending a health facility in Botswana estimated 
the prevalence of retinopathy to be only 9.2% and was the third most common eye condition 
after refractive error and cataract77.  Another study completed in 2011, found the prevalence of 
DR to be 17.7% among the diabetics on the national screening register in Botswana78. 
2.5.1 Diabetic retinopathy screening service (DRSS) in Botswana 
Retinopathy diagnosed early, followed closely and treated timeously with retinal laser therapy 
prevents blinding proliferative retinopathy and most importantly blindness79. Therefore, both 
the IDF and WHO vision 2020 guidelines recommend early detection of DR by means of DR 
screening. The DRS Service in Botswana was developed by prevention of blindness program 
(PoB) in the ministry of health in October 2009 with the help of a UK based charity called 
Addenbrook’s Abroad80.  
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The screening was first done at Princes Marina hospital, a Referral facility in Gaborone until 
end of 2011 when it moved to Block 6 clinic. The DRSS went national in 2012 and included 3 
additional screening sites, Donga Clinic in Francistown, Sekgoma Memorial Hospital in 
Serowe and Letsholathebe Hospital in Maun. Block 6 Clinic is still the designated “diabetic 
centre of excellence” and offers a comprehensive array of services for the overall management 
of diabetic patients. The DR screening is done by 2 trained ophthalmic nurses using a non-
mydriatic fundus camera. The nurses have also been trained to grade the pictures.  However, 
attendance has been consistently low at the clinic and the “did not attend” (DNA) rate is 
estimated to be around 30% .80 
2.6 Conclusion 
The above discussion has highlighted the significant burden of disease that diabetes and its 
most common ocular complication, Diabetic retinopathy, pose to our community. It is clear 
that the health systems particularly in developing nations such as Botswana, need to be better 
equipped to avoid the preventable blindness that occurs due to DR. Development of the 
screening programme is a step in the right direction but more data is needed in order for us to 
achieve maximum public health benefit from the population based programme. 
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The Prevalence and Determinants of Diabetic Retinopathy in Botswana: Findings from a 
Screening Programme 
Nuru S. Omari 
3.1 ABSTRACT 
3.1.1 Background 
The International Diabetes Federation estimates that the number of adults with diabetes in Africa will 
increase by 98% by the year 2030. The importance of diabetic retinopathy as a cause of blindness has 
increased because of longevity and a decline in the other preventable causes of blindness in developing 
countries. Retinopathy diagnosed early, followed closely, and treated timeously with retinal laser 
therapy, prevents blinding retinopathy. The objective of the study is to determine the prevalence of 
Diabetic Retinopathy, its determinants and the acceptability as well as accessibility of the screening 
service by patients. 
3.1.2 Methods 
The study is a cross-sectional study conducted at Gaborone diabetic retinopathy screening clinic. 
Convenience sampling was used where every eligible patient that arrived for DR screening and had 
consented was included in the study. Basic descriptive statistics of the study sample were reported and 
a multivariate analysis was performed with DR as the outcome of interest. 
3.1.3 Results 
A total of 220 participants attended the clinic between 12th of January and 6th of February 2015. The 
mean age of the participants was 55.96 (p=0.32) years and females comprised the majority 65.45% (n= 
144, p=0.33)) of participants. A fifth of the participants (n=43, p=0.67) felt they had poor knowledge 
of diabetes and 25.91% (n=57, p=0.96) stated they did not understand the purpose of screening. Only 
63.64% (n=140, p=0.46) reported to always being compliant with their medication and compliance did 
not differ significantly between those who had retinopathy and those who did not. Traditional medicine 
use was reported in 16.36% of the participants (n=36, p=0.33).  Diabetic Retinopathy was found in 
31.82% (n=70) of the population and of those, 3 participants (1.36%) had referable DR. Maculopathy 
was found in 21.82% (n=48) of participants. Increasing household number and years living with DM 




The prevalence of diabetic retinopathy has increased in our population compared to previous studies. 
The number of Diabetics attending the DR screening service in Gaborone has also increased but 
continuous diabetes health education cannot be over emphasized. Incorporation of local cultural values 
into the overall management of the disease is the best way to increase patient compliance. 
3.2 Introduction 
The World Health Organisation (WHO) estimates that there are more than 170 million people 
with diabetes mellitus (DM) worldwide and this figure is expected to rise to 366 million in 
20301. The most rapid growth is expected in low and middle income countries amongst 
working age populations2. The International Diabetes Federation (IDF) has estimated that the 
number of adults with DM in Africa will increase from 12.1 million to 23.9 million by the year 
2030, a 98% increase. This is believed to be driven by the increase in urbanisation, sedentary 
lifestyles, obesity, population overgrowth and aging as well as successes in combating 
communicable diseases in the region1. Sub-Saharan Africa (SSA), like the rest of the world, is 
experiencing an increasing prevalence of diabetes alongside other non-communicable diseases, 
a so called “double burden” of disease3.  
Type 2 diabetes (T2DM) is the predominant form of diabetes in SSA4 and accounts for more 
than 90% of the cases, whilst type 1 diabetes mellitus, gestational diabetes and other specific 
types constitute less than 10%. Risk factors for the development of T2DM include obesity, 
ageing, and physical inactivity, often arising as a result of socioeconomic dynamics5.  Recent 
evidence suggests that antiretroviral treatment has been shown to increase obesity and insulin 
resistance6, showing that communicable and non-communicable diseases are not separate 
entities as once considered.  
Nearly 50% of all people with Diabetes are unaware that they have the condition7, meaning 
damage may have already occurred even at diagnosis. The risk of developing vascular 
complications of diabetes increases with increasing concentrations of hyperglycaemia and 
duration of disease8. There is strong evidence from cohort studies of diabetic populations that 
in addition to duration of diabetes and metabolic control; blood pressure, cholesterol and 
ethnic/genetic factors are the main known determinants of vascular complications9. Several 
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studies have shown that microvascular complications which include retinopathy, nephropathy 
and neuropathy are more common and occur earlier in the course of the disease10. It is reported 
that some cases of retinopathy can be seen as long as seven years before diagnosis of DM11.  
Diabetics of African origin are thought to be at greater risk of developing microvascular 
complications compared to Caucasians12. Genetic predisposition may play a role, but most 
likely late diagnosis of diabetes, poor metabolic control and non-standardized diagnostic 
procedures may account for the difference from other populations13. 
Diabetic retinopathy may be the most common microvascular complication of Diabetes. 
Diabetic eye disease comprises a group of eye conditions that affect people with diabetes, 
namely, diabetic retinopathy, diabetic macular edema (DME), cataract, and glaucoma14. It is 
thought to evolve through several stages: background retinopathy progresses to either DME or 
proliferative retinopathy (PDR) or a combination of the two15. Both DME and PDR can 
independently lead to blindness hence they are sometimes collectively referred to as “sight 
threatening DR (STDR)”.  
Without treatment, it is reported that 50% of patients with proliferative retinopathy/retinal 
neovascularisation will become blind within 5 years16. In recent years, due to better access to 
high quality cataract surgical services, DR is becoming a more significant cause of blindness17.  
The effectiveness of photocoagulation therapy suggests that there is the potential for a national 
screening programme to bring about a major reduction in blindness from retinopathy. Early 
identification of diabetic retinopathy is also cost-effective; as previous modelling studies have 
demonstrated potential savings of millions of dollars if a patient evaluation results in 
appropriate photocoagulation18. Unfortunately, despite the consensus that examinations for the 
presence of diabetic retinopathy can reduce the risk of blindness, a large number of individuals 
with diabetes still do not receive such examinations.   
DR screening programmes continue to have difficulty in attaining good attendance rates. The 
Botswana DRSS quotes their estimated “did not attend” (DNA) rate to be around 30%19. 
Evaluation of the screening programme in Botswana will therefore give us an understanding 
into the distribution and the determinants of DR. More importantly, this study will allow us to 
have better insight into patients’ attitudes and understanding of the screening programme and 
diabetes in as a whole. 
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3.3 Study Objectives 
The primary objective of the study is to determine the prevalence of diabetic retinopathy (DR) 
and Sight Threatening DR in those that present for retinopathy screening in Gaborone, 
Botswana. The study sample at the primary clinic is presumed to be representative of the 
diabetic community.  
The following objectives are outlined for the study: 
1. To determine the prevalence of “any” DR in the patients screened at the centre.
2. To determine the proportion of “referable” DR amongst those that have retinopathy.
3. To assess how well the patients presenting for screening manage their diabetes.
4. To determine the accessibility of the screening service by the surrounding community.
5. To determine the level of awareness and acceptability of the screening service.
6. To explore the association between diabetic retinopathy and other predictor variables.
3.4 Methodology 
3.4.1 Study design and setting 
The study was a cross-sectional survey conducted in Gaborone at a primary healthcare clinic. 
The study ran for 5 weeks; from the 12th of January 2015 to the 6th of February 2015. Every 
eligible patient that arrived for DR screening services during that time and had consented was 
included in the study. 
3.4.2 Population and recruitment 
The study population were Type 1 and Type 2 diabetics above the age of 18years presenting to 
the eye clinic for purposes of DR screening only. The eye clinic is located within a primary 
healthcare clinic that has become the designated diabetes centre of excellence in Block 6 region 
of Gaborone. Some participants had been referred from surrounding health facilities 
specifically for DR screening. 
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Convenience sampling was used where consecutive patients were asked to participate in the 
study. Participation was voluntary and no form of incentive was provided. Explanation and 
consent was conducted in the patients’ first language, Setswana. Eligible participants were 
recruited from the clinic waiting area, explanation of the study was given and consent was 
sought. The questionnaire was researcher administered to each participant in a private room in 
the eye clinic.  
3.4.3 Screening for Diabetic Retinopathy in Botswana 
The DR screening Service in Botswana was developed by the prevention of blindness program 
(PoB) in the ministry of health in October 2009 with the help of a UK based charity called 
Addenbrook’s Abroad23. 
Block 6 Clinic in Gaborone is the designated “diabetic centre of excellence” and offers a 
comprehensive array of services for the overall management of diabetic patients. Visual Acuity 
(VA) in the better eye was recorded using Snellens’ chart and the World Health Organization 
categories of visual impairment were used to define vision status (WHO, 2004). Normal vision 
is >6/18; visually impaired is between 6/18 - 3/60 and blind is <3/60. Pinhole testing was used 
to ascertain best corrected VA as opposed to presenting VA.  
This was done to exclude refractive error, particularly presbyopia, as a cause for visual 
impairment in this population. Mydriatic drops such as 1% tropicamide were then instilled into 
the eyes before retinal images were captured using a non-mydriatic digital fundus camera. The 
trained nurses performed both the screening as well as grading of the retinal images. Patients 
who have retinopathy that threatens their vision were referred to the ophthalmologist for further 
management. 
3.4.4 Grading of Diabetic Retinopathy 
The grading tool was based on the United Kingdom National Health Service (NHS) grading 
protocol but was revised by the Botswana Ministry of Health (MOH) prevention of blindness 
office. Most classification systems for DR are based on landmark studies that tracked the 
appearance and progression of the disease [ETDRS study]. The protocol grades retinopathy 
from R0 to R3 and maculopathy as a separate grade from M0 to M2 (see table below). 
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Participants’ fundus were graded and placed into one of three categories:  
1. “NO” retinopathy (grade R0/M0). Patient is asked to re-screen in 12 months.
2. “NON-REFERRABLE” retinopathy (R1-R2/M1). Patient is advised good glycaemic
control and lifestyle modifications encouraged. Asked to re-screen earlier than 12
months.
3. “REFERRABLE” retinopathy (>R2/M1). Also known as sight threatening DR.
Referral to ophthalmologist, may be immediate or within 4 weeks depending on the
severity of disease.
The “ANY” retinopathy (>R0) category is the sum of referable and non-referable DR cases. 
This was done mainly for ease of statistical analysis, so that binary outcome can be 
ontained. 
3.5 Data management and analysis 
Data was collected by study personnel and recorded in participant questionnaires for entry into 
a Microsoft Excel database for storage. The data was cleaned using pivot tables in excel and 
exported to STATA version 14 (Stata Corp. College Station Texas) for analysis. Each 
participant was assigned a unique study number. The Microsoft Excel database only used the 
study number and not the name of participant therefore confidentiality was maintained at all 
times in the study. Basic descriptive statistics of the study sample were reported and a 
multivariate analysis was performed with DR as the outcome of interest.  
The various risk factors collected from the participants were used to determine their association 
with the DR outcome. The level of significance for the estimates was set at 15% to increase the 
chances of seeing the associations between the different covariates. 
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Table 1- Retinopathy and maculopathy grading protocol for Botswana DRS Programme. 
Adapted from NHS, UK Protocols revised by Botswana OPN and Office of Prevention of 





RO No Changes No Retinopathy Re-screen in 
12months 
MO No Changes No Maculopathy Re-screen in 
12months 




Background / Mild 
/Non –proliferative 
Retinopathy 
Re-screen in 6 /12 to 
12months 
R2 Multiple deep, round or 
blot haemorrhage / 




Moderate or severe / 
Pre-proliferative 
Retinopathy 
Re-screen in 3/12 
M1 
(if M1 is present, R1 
MUST, be selected) 
MA/Haemorrhages 
Within I DD from fovea 
Maculopathy Re-screen in 6 /12
M2 
Referable 
* R2 PLUS below
*Exudates within 1DD
of fovea /circinate or
group of exudates within
macula/retinal
thickening within 1 DD
Maculopathy Routine referral in 
4/52 (4 weeks) 
R3 New vessels on disc 
(NVD)/New vessels 
elsewhere (NVE)/  
Pre-retinal or vitreous 
haemorrhage/pre-retinal 




Urgent Referral in 
2/52 (2 weeks) 






There were 227 eligible participants enrolled into the study. Every participant who was asked 
to participate in study agreed to take part. Seven “ungraded” participants were excluded 
because their retinas could not be viewed due to corneal opacities or cataract. The analysis used 
the remaining 220 participants [Table 2]. 
3.6.1 Demographic data 
The mean age of the participants was 55.96 years (SD 13.8). Females comprised almost two-
thirds of the participants, (n=144; 65.5%) compared to 34.55% (n=76) males. Most of the 
participants had only completed primary school (n=91; 41.4%) with 19.1% (n=42) having 
attained tertiary education. The majority of the participants were not employed (n=128; 58.2%) 
and the median years living with diabetes was 6 years (IQR 2-11.5years). Those who had 
retinopathy had been living with DM for 8.5 years compared with 5years for those without 
retinopathy 
3.6.2 Vision and DR status 
Almost all of the participants, (n=214; 97.3%) had normal vision. Five participants (2.3 %) 
were visually impaired and 1 participant was blind. Any Diabetic Retinopathy was found in 
31.82% (n=70) of the population and of those, 3 participants (1.36%) had referable DR. 
Maculopathy was found in 21.82% (n=48) of participants, (n=15; 6.8%) 15 of those 
participants had maculopathy requiring referral to a specialist.  
3.6.3 Patient self-management 
Only 63.64% (n=140) reported to always be compliant with their medication and compliance 
did not differ significantly between those who had retinopathy and those who did not. The most 
popular medication regime used was oral hypoglycaemics (n=141; 64.1%), followed by 
combination of oral and insulin (n=48; 21.8%) then lastly only Insulin use in 25 of the 
participants (11.4%). Traditional medicine use was reported in 16.36% of the participants 
(n=36). The majority of the participants did not require a care taker (n=193; 87.7%) and those 
that did, their primary caretaker was their child and not a spouse. 
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3.6.4 Knowledge, accessibility and acceptability 
A fifth of the participants (n=43) felt they had poor knowledge of diabetes, the rest (n=177; 
80.5%), reported good to average knowledge of the disease. Half the participants (n=112; 
50.9%) took 30 minutes or less to arrive at the clinic.  
Only 10.9% of the participants’ (n=24) took more than an hour to arrive at the clinic. A quarter 
of participants stated they did not understand the purpose of screening 25.91% (n=57). 
3.6.5 Association between DR and predictor variables 
Increasing number of people per household number and years living with DM were the only 
variables found to have a significant association with development of diabetic retinopathy. In 
our study, while holding everything constant, a 1 person increase in household number resulted 
in a 9.5% increase in risk of retinopathy in those with retinopathy compared with those without 
retinopathy (p=0.0120). Also, a 1-year increase in years living with DM results in an 8.7% 
increase in risk of retinopathy in those with retinopathy compared with those without 
retinopathy (P<0.05). 
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Age, mean (±SD) 56.0 (13.8) 57.3 (12.2) 55.3 (14.5) 0.322 
Household number, median (IQR) 4 (3-6) 5 (3-6) 4 (3-6) 0.191 






























Years with Diabetes Mellitus, median (IQR) 6 (2-11.5) 8.5 (5-15) 5 (2-9) <0.0001 
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Our study found that almost a third of the diabetics at the screening service had some form of 
DR. This is a relatively high prevalence compared to previous studies done in Botswana among 
even though the previous studies looked at the facility based diabetic population similar to our 
study. Our findings are in keeping with a systematic review20 of the studies done in 21 African 
countries in 2012 where the prevalence of any retinopathy was found to be between 30.2-31.6% 
and STDR was found to be 0.9 - 1.3%. The reason for that may be that uptake of the screening 
service is improving hence a more accurate reflection of the true burden of disease. 
The study findings showed that participant compliance with medication was not optimal. It is 
well known that patient compliance in chronic disease self-management such as diabetes is 
very poor, our findings showed only two thirds admitted to always take their medication. Yet - 
there is evidence for and reference to the fact that blood glucose measurements were seldom 
taken and medication doses/regimens seldom altered/amended at primary care level - so while 
patients report compliance their management may still be sub-optimal. In addition to that, a 
significant proportion of the participants admitted to traditional medicine use and that may be 
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a contributor in the poor compliance observed. The WHO estimates that In Africa, up to 80% 
of the population uses traditional medicine to help meet their health care needs21.  
Information bias where participants withhold certain information for fear of judgment may 
underestimate the true figure. More studies are needed to see the actual effect and extent of 
traditional medicine use in diabetics of Botswana. It is not surprising that majority of the 
participants were taking oral medication, due to high prevalence of type 2 diabetes in the 
region. Interestingly, those with retinopathy were more likely to be taking a combination of 
oral and insulin therapy compared to those without retinopathy. This may also imply a more 
aggressive form of diabetes or more co-morbidity or co-existing risk factors, more advanced 
disease in general. 
A significant proportion of the participants in this study felt they did not understand the purpose 
of DR screening for diabetic retinopathy. We used this variable as a proxy to measure 
acceptability of the screening service in this population. We are aware the limitation of 
selection bias in assessing acceptability in a population that has already accessed the health 
service. Ideally population based studies would have better answered this question and allowed 
us to better understand the possible barriers. Having said that, the information gained in our 
study does suggest that continued diabetes health education will be of use in our population. 
The information gathered in the study will also be valuable as a baseline for comparison in 
future studies.  
Years of living with DM is a well-known and important determinant of development of DR. A 
longitudinal study reported that after 20 years of diabetes almost all patients with Type 1 DM 
developed retinopathy, while approximately two-third of the patients with Type 2 DM 
developed retinopathy irrespective of their blood sugar control22. Hence not surprising that it 
was significantly associated with development of Diabetic retinopathy. Age is also a commonly 
reported risk factor for development and progression of DR but in this study the association 
between age and retinopathy was not significant. Reasons for this might be due to relatively 
small sample size and the skewed age distribution which if adjusted for might have yielded 
different results.  
Attendance rates could be improved at the clinic and the “did not attend” (DNA) percentage is 
estimated to be around 30%. In national population-based screening programmes, the desirable 
target uptake is 80% which is difficult to achieve23. Recall systems need to be put into place to 
14 
ensure better attendance rates such as short message system (SMS) alerts and phone call 
reminders. Limitations of this study include use of researcher administered questionnaire as 
opposed to self-questionnaire.  
This may have exposed the study to biases resulting from participants’ fear of judgment hence 
less truthful responses. Another limitation may have been the use of a quantitative study design 
to look at patient’s perspectives on diabetes and the screening programme. A qualitative study 
may have allowed deeper understanding of the patient issues; such a study may be planned in 
future. 
3.8 Conclusion 
Diabetic retinopathy is prevalent in our community; this study shows that the prevalence has 
increased from approximately 10-15% to 30% compared to studies in the past. The number of 
Diabetics attending the DR screening service in Gaborone has increased but more effort needs 
to be made to encourage diabetics to attend for screening and to return for subsequent visits. 
Continuous diabetes health education cannot be over emphasized and incorporation of local 
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